Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prime MedicinePRME -2.80%25 14-Day RSI is 41.98 as of Jul. 19, 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,425 Biotechnology companies, Prime Medicine ranks better than 65.54% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-19), Prime Medicine's 14-Day RSI is 41.98.
The industry rank for Prime Medicine's 14-Day RSI or its related term are showing as below:
PRME's 14-Day RSI is ranked better than 65.54% of 1425
companies
in the Biotechnology industry
Industry Median: 45.58
vs PRME: 41.98
Prime Medicine (NAS:PRME) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Prime Medicine 14-Day RSI Related Terms
PRME vs EIKN, CRMD, STTK: 14-Day RSI Comparison
For the Biotechnology subindustry, Prime Medicine's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Prime Medicine's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a 14-Day RSI of 41.98 as of Jul. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #491 out of 1425 companies in the Biotechnology industry, placing it in the top 34.5%.
Is Prime Medicine's 14-Day RSI too high?
Prime Medicine's current 14-Day RSI is 41.98. The Biotechnology industry median 14-Day RSI is 45.58. Prime Medicine's value of 41.98 is 7.9% below this industry median. Based on the distribution chart, Prime Medicine ranks #491 out of 1425 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's 14-Day RSI compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #491 out of 1425 companies for 14-Day RSI. This puts Prime Medicine in the upper half of its industry. The industry median 14-Day RSI is 45.58. Prime Medicine's value of 41.98 is 7.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.58, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current 14-Day RSI of 41.98 is 7.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current 14-Day RSI is 41.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current 14-Day RSI of 41.98. The current 14-Day RSI is 41.98 and 7.9% below the Biotechnology industry median of 45.58. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Prime Medicine (PRME), the current 14-Day RSI is 41.98 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
